Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings DaShenLin Pharmaceutical Group Co., Ltd.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: DaShenLin Pharmaceutical Group Co., Ltd.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With regards to fundamentals, the enterprise value to sales ratio is at 0.55 for the current period. Therefore, the company is undervalued.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: DaShenLin Pharmaceutical Group Co., Ltd.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.95B
BB
15.83B
AA
7.38B
AA
6.21B
AAA
3.98B
AAA
3.3B
BBB
3.12B
AAA
2.78B -
BBB
- -
2.62B - - - - -
1.59B
AA
Average 4.98B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 603233 Stock
  4. Ratings DaShenLin Pharmaceutical Group Co., Ltd.